SLC5A2 and diabetes mellitus: It is possible that greater cardioprotective benefits would have been observed with a more severe hyperglycemic model; however, improved cardiovascular outcomes with selective SGLT2 inhibition is seen across the spectrum of HbA1c in patients with and without diabetes (McMurray et al., 2019; Packer et al., 2020; Petrie et al., 2020; Anker et al., 2021), and a more severe model may have compromised renal morphology and drug action further.